Podcast

In this podcast, recorded by and featured on the Cell Culture Dish Blog, we spoke with Dr. George Wang, Vice President of Discovery and Preclinical Services at WuXi Biologics, where he shares insights on the critical role of developability assessments in antibody therapeutics discovery. The podcast commences with Dr. Wang defining developability and its role in achieving scalable production during CMC development, crucial for large-scale manufacturing prior to clinical trials. Dr. Wang then emphasizes the importance of identifying and addressing developability concerns early in the discovery stage to mitigate risks and ensure cost-effective development, providing examples where developability studies have helped mitigate unforeseen costs and timeline disruptions during the biologics discovery and preclinical development phases. He underscores that assessing developability can uncover issues with product aggregation, stability, solubility, or manufacturing efficiencies.

Furthermore, Dr. Wang discusses WuXi Biologics’ approach to integrating developability assessments into early-stage discovery programs and how the organization leverages its extensive experience and expertise from both their discovery and development teams to address any issues that may arise during developability assessments. He provides detailed explanations of how the organization employs high-throughput screening methods, in silico analysis, and advanced analytical tools to evaluate developability attributes of potential candidates at multiple time points throughout the discovery to development continuum. By identifying and addressing developability concerns upfront, WuXi Biologics enables its clients to make informed decisions, optimize lead candidates, and streamline the transition from discovery to IND filing.